Participant flow

HIPEC for Peritoneal Carcinomatosis · Source last updated 2024-10-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   HIPEC + 40 milligrams (mg) of Mitomycin C. Mitomycin C, 30 mg, were administered into the inflow line of the perfusion circuit once target temperature was reached. At the 60 minute time point of the perfusion, Mitomycin C, 10 mg, was administered into the inflow line of the perfusion circuit. Once the 90-minute perfusion period had elapsed, the perfusate was drained into the waste reservoir. The peritoneal cavity was rinsed/washed-out. hyperthermic intraperitoneal chemotherapy (HIPEC) Mitomycin C

   id

   FG000

   title

   HIPEC + Mitomycin C

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         5

      type

      Lost to Follow-up

   2. reasons

      1. group Id

         FG000

         num Subjects

         17

      type

      Death

   3. reasons

      1. group Id

         FG000

         num Subjects

         14

      type

      Not Evaluable (Surgery and/or Treatment aborted but still enrolled)

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         51

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         15

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         36

      type

      NOT COMPLETED

   title

   Overall Study

recruitment Details

Participants were recruited at 1 clinical site between early 2011 and March 2020. The first participant was enrolled into the study in November 2011.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice